S-Space

Browse

Subject

Jump to a point in the index

Or type in a year

Sort by
In order
Results/Page
Authors/record

Showing results 1 to 40 of 61

Issue Date	Title / Author(s) / Citation	File
2005	(A)Combination of HER2 status and the St. Gallen classification provides useful information on prognosis in node-negative breast cancer 선종무	link
2006	HER2 유전자가 증폭된 위암 세포주에 대한 trastuzumab의 성장억제 효과와 그 기전에 대한 연구 김선영	link
2008-01	Trastuzumab inhibits the growth of human gastric cancer cell lines with HER2 amplification synergistically with cisplatin Kim, Sun Young; Kim, Hwang Phill; Kim, Yu Jung; Oh, Do Youn; Im, Seock-Ah; Lee, Dongsoon; Jong, Hyun-Soon; Kim, Tae-You; Bang, Yung-Jue International Journal of Oncology, Vol.32 No.1, pp.89-95	DOI
2008-04	Assessment of a HER2 scoring system for gastric cancer: results from a validation study Hofmann, M; Stoss, O; Shi, D; Buttner, R; Vijver, M van de; Kim, W; Ochiai, A; Ruschoff, J; Henkel, T Histopathology 2008; 52; 797-805	link
2008-10	Ongoing debates in the assessment of the HER2 status in breast cancer: A comparative analysis by immunohistochemistry and FISH using original FDA and ASCO/CAP guidelines Ko, Hyoungsuk; Seol, Hyesil; Kim, Wook Youn; Im, Seock-Ah; Han, Wonshik; Noh, Dong-Young; Jeon, Yoon Kyung; Park, In Ae Bas Appl Pathol 2008; 1: 182-188	DOI
2009-10	Weekly Paclitaxel and Trastuzumab as a First-Line Therapy in Patients with HER2-Overexpressing Metastatic Breast Cancer: Magnitude of HER2/neu Amplification as a Predictive Factor for Efficacy Han, Hye-Suk; Kim, Jin-Soo; Park, Jin Hyun; Jeon, Yoon Kyung; Lee, Keun-Wook; Oh, Do-Youn; Kim, Jee Hyun; Park, So Yeon; Im, Seock-Ah; Kim, Tae-You; Park, In Ae; Bang, Yung-Jue Journal of Korean Medical Science, Vol.24 No.5, pp.910-917	view file DOI
2010-08	Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial Bang, Yung-Jue; Van Cutsem, Eric; Feyereislova, Andrea; Chung, Hyun C.; Shen, Lin; Sawaki, Akira; Lordick, Florian; Ohtsu, Atsushi; Omuro, Yasushi; Satoh, Taroh; Aprile, Giuseppe; Kulikov, Evgeny; Hill, Julie; Lehle, Michaela; Ruschoff, Josef; Kang, Yoon-Koo The Lancet, Vol.376 No.9742, pp.687-697	DOI
2011-02	맞춤 약물 요법 관련 진단 검사의 비용-효과 분석 고은지	link
2011-05	Discordant human epidermal growth factor receptor 2 and hormone receptor status in primary and metastatic breast cancer and response to trastuzumab Chang, Hye Jung; Han, Sae-Won; Oh, Do-Youn; Im, Seock-Ah; Jeon, Yoon Kyung; Park, In Ae; Han, Wonshick; Noh, Dong-Young; Bang, Yung-Jue; Kim, Tae-You Japanese Journal of Clinical Oncology, Vol.41 No.5, pp.593-599	DOI
2011-06	Clinicopathologic characteristics of patients with stage III/IV (M 0) advanced gastric cancer, according to HER2 status assessed by immunohistochemistry and fluorescence in situ hybridization Im, Seock-Ah; Kim, Jin Won; Kim, Jin-Soo; Kim, Min A.; Jordan, Bruce; Pickl, Marlene; Han, Sae-Won; Oh, Do-Youn; Lee, Hyuk Joon; Kim, Tae-You; Kim, Woo Ho; Yang, Han-Kwang; Bang, Yung-Jue Diagnostic Molecular Pathology, Vol.20 No.2, pp.94-100	DOI
2011-11	Heterogeneous amplification of ERBB2 in primary lesions is responsible for the discordant ERBB2 status of primary and metastatic lesions in gastric carcinoma Kim, Min A.; Lee, Hyuk-Joon; Yang, Han-Kwang; Bang, Yung-Jue; Kim, Woo Ho Histopathology, Vol.59 No.5, pp.822-831	DOI
2012-01	Pertuzumab plus Trastuzumab plus Docetaxel for Metastatic Breast Cancer Baselga, Jose; Cortes, Javier; Kim, Sung-Bae; Im, Seock-Ah; Hegg, Roberto; Im, Young-Hyuck; Roman, Laslo; Pedrini, Jose Luiz; Pienkowski, Tadeusz; Knott, Adam; Clark, Emma; Benyunes, Mark C.; Ross, Graham; Swain, Sandra M. New England Journal of Medicine, Vol.366 No.2, pp.109-119	DOI
2012-09	Advances in the Management of HER2-positive Advanced Gastric and Gastroesophageal Junction Cancer Bang, Yung-Jue Journal of Clinical Gastroenterology, Vol.46 No.8, pp.637-648	DOI
2013-07	HER2/CEP17 ratio and HER2 immunohistochemistry predict clinical outcome after first-line trastuzumab plus taxane chemotherapy in patients with HER2 fluorescence in situ hybridization-positive metastatic breast cancer Kim, Ji-Won; Kim, Jee Hyun; Im, Seock-Ah; Kim, Yu Jung; Han, Hye-Suk; Kim, Jin-Soo; Lee, Kyung-Hun; Kim, Tae-Yong; Han, Sae-Won; Jeon, Yoon Kyung; Oh, Do-Youn; Kim, Tae-You; Park, In Ae Cancer Chemotherapy and Pharmacology, Vol.72 No.1, pp.109-115	DOI
2014-02	Identification of predictive biomarkers and the mechanisms of acquired resistance to epidermal growth factor receptor inhibitors 김황필	view file
2014-02	The Comparison of HER2 Targetability between Affibody and Antibody in Nude Mice Bearing Human Breast Cancer Xenograft 임일한	view file
2014-06	Testican-1-mediated epithelial-mesenchymal transition signaling confers acquired resistance to lapatinib in HER2-positive gastric cancer Kim, H-P; Han, S-W; Song, S-H; Jeong, E-G; Lee, M-Y; Hwang, D.; Im, S-A; Bang, Y-J; Kim, T-Y Oncogene, Vol.33 No.25, pp.3334-3341	DOI
2014-07	Quality of Life in the Trastuzumab for Gastric Cancer Trial Satoh, Taroh; Bang, Yung-Jue; Gotovkin, Evgeny A.; Hamamoto, Yasuo; Kang, Yoon-Koo; Moiseyenko, Vladimir M.; Ohtsu, Atsushi; Van Cutsem, Eric; Al-Sakaff, Nedal; Urspruch, Alexa; Hill, Julie; Weber, Harald A.; Chung, Hyun-Cheol Oncologist, Vol.19 No.7, pp.712-719	DOI
2014-08	A phase IIa dose-finding and safety study of first-line pertuzumab in combination with trastuzumab, capecitabine and cisplatin in patients with HER2-positive advanced gastric cancer Kang, Y-K; Rha, S. Y.; Tassone, P.; Barriuso, J.; Yu, R.; Szado, T.; Garg, A.; Bang, Y-J British Journal of Cancer, Vol.111 No.4, pp.660-666	DOI
2014-08	Immunohistochemical Features Associated with Sensitivity to Lapatinib-plus-Capecitabine and Resistance to Trastuzumab in HER2-positive Breast Cancer Cha, Yongjun; Han, Sae-Won; Seol, Hyesil; Oh, Do-Youn; Im, Seock-Ah; Bang, Yung-Jue; Park, In Ae; Han, Wonshik; Noh, Dong-Young; Kim, Tae-You Anticancer Research, Vol.34 No.8, pp.4275-4280
2014-12	HER2 Heterogeneity Affects Trastuzumab Responses and Survival in Patients With HER2-Positive Metastatic Breast Cancer Lee, Hee Jin; Seo, An Na; Kim, Eun Joo; Jang, Min Hye; Suh, Koung Jin; Ryu, Han Suk; Kim, Yu Jung; Kim, Jee Hyun; Im, Seock-Ah; Gong, Gyungyub; Jung, Kyung Hae; Park, In Ae; Park, So Yeon American Journal of Clinical Pathology, Vol.142 No.6, pp.755-766	DOI
2015-01	Prognostic and predictive values of EGFR overexpression and EGFR copy number alteration in HER2-positive breast cancer Lee, H. J.; Seo, A. N.; Kim, E. J.; Jang, M. H.; Kim, Y. J.; Kim, J. H.; Kim, S. -W.; Ryu, H. S.; Park, I. A.; Im, S. -A.; Gong, G.; Jung, K. H.; Kim, H. J.; Park, S. Y. British Journal of Cancer, Vol.112 No.1, pp.103-111	DOI
2015-02	Studies of synergistic antibody combination for treatment of patients with HER2-positive cancer 고봉국	view file
2015-02	Assessment of HER2 status in invasive breast cancer with increased centromere 17 copy number by fluorescence in situ hybridization 장민혜	view file
2015-06	Optimal patient selection for trastuzumab treatment in HER2-positive advanced gastric cancer Ock, Chan-Young; Lee, Keun-Wook; Kim, Jin Won; Kim, Jin-Soo; Kim, Tae-Yong; Lee, Kyung-Hun; Han, Sae-Won; Im, Seock-Ah; Kim, Tae-You; Kim, Woo Ho; Bang, Yung-Jue; Oh, Do-Youn Clinical Cancer Research, Vol.21 No.11, pp.2520-2529	DOI
2016-01	Amphiregulin confers trastuzumab resistance via AKT and ERK activation in HER2-positive breast cancer Kim, Ji-Won; Kim, Debora K.; Min, Ahrum; Lee, Kyung-Hun; Nam, Hyun-Jin; Kim, Jee Hyun; Kim, Jin-Soo; Kim, Tae-Yong; Im, Seock-Ah; Park, In Ae Journal of Cancer Research and Clinical Oncology, Vol.142 No.1, pp.157-165	DOI
2016-02	A synergistic interaction between human epidermal growth factor receptor 2/neu and c-Jun N-terminal kinase promotes gastric cancer cell migration and invasion 최이슬	view file
2016-02	Interaction between FOXO1 and human epidermal growth factor receptor 2/neu regulates gastric tumor growth and metastasis 고영산	view file
2016-02	Improvement in anti-cancer activity and binding affinity of the therapeutic anti-HER2 monoclonal antibody and bioprocess development 문승기	view file
2016-02	Lapatinib in combination with capecitabine plus oxaliplatin in human epidermal growth factor receptor 2-positive advanced or metastatic gastric, esophageal, or gastroesophageal adenocarcinoma: TRIO-013/LOGiC-A randomized phase III trial Hecht, J. Randolph; Bang, Yung-Jue; Qin, Shukui K.; Chung, Hyun C.; Xu, Jianming M.; Park, Joon O.; Jeziorski, Krzysztof; Shparyk, Yaroslav; Hoff, Paulo M.; Sobrero, Alberto; Salman, Pamela; Li, Jin; Protsenko, Svetlana A.; Wainberg, Zev A.; Buyse, Marc; Afenjar, Karen; Houe, Vincent; Garcia, Agathe; Kaneko, Tomomi; Huang, Yingjie; Khan-Wasti, Saba; Santillana, Sergio; Press, Michael F.; Slamon, Dennis Journal of Clinical Oncology, Vol.34 No.5, pp.443-451	DOI
2016-02	Pertuzumab in gastrointestinal cancer Oh, Do-Youn; Bang, Yung-Jue Expert Opinion on Biological Therapy, Vol.16 No.2, pp.243-253	DOI
2016-03	Substitution of heavy complementarity determining region 3 (CDR-H3) residues can synergistically enhance functional activity of antibody and its binding affinity to HER2 antigen Moon, Seung Kee; Park, So Ra; Park, Ami; Oh, Hyun Mi; Shin, Hyun Jung; Jeon, Eun Ju; Kim, Seiwhan; Park, Hyun June; Yeon, Young Joo; Yoo, Young Je Molecules and Cells, Vol.39 No.3, pp.217-228	view file DOI
2016-04	Metabolic landscape of advanced gastric cancer according to HER2 and its prognostic implications Ock, Chan-Young; Kim, Tae-Yong; Lee, Kyung-Hun; Han, Sae-Won; Im, Seock-Ah; Kim, Tae-You; Bang, Yung-Jue; Oh, Do-Youn Gastric Cancer, Vol.19 No.2, pp.421-430	DOI
2016-05	Expression of breast cancer stem cell markers as predictors of prognosis and response to trastuzumab in HER2-positive breast cancer Seo, An Na; Lee, Hee Jin; Kim, Eun Joo; Jang, Min Hye; Kim, Yu Jung; Kim, Jee Hyun; Kim, Sung-Won; Ryu, Han Suk; Park, In Ae; Im, Seock-Ah; Gong, Gyungyub; Jung, Kyung Hae; Kim, Hee Jeong; Park, So Yeon British Journal of Cancer, Vol.114 No.10, pp.1109-1116	DOI
2016-09	Therapeutic implication of HER2 in advanced biliary tract cancer Nam, Ah-Rong; Kim, Ji-Won; Cha, Yongjun; Ha, Hyerim; Park, Ji Eun; Bang, Ju-Hee; Jin, Mei Hua; Lee, Kyung-Hun; Kim, Tae-Yong; Han, Sae-Won; Im, Seock-Ah; Kim, Tae-You; Oh, Do-Youn; Bang, Yung-Jue Oncotarget, Vol.7 No.36, pp.58007-58021	DOI
2016-10	Phase II trial of dacomitinib in patients with HER2-positive gastric cancer Oh, Do-Youn; Lee, Kewn-Wook; Cho, Jae Yong; Kang, Won Ki; Im, Seock-Ah; Kim, Jin Won; Bang, Yung-Jue Gastric Cancer, Vol.19 No.4, pp.1095-1103	DOI
2016-12	Proposal of a Provisional Classification of Sebaceous Carcinoma Based on Hormone Receptor Expression and HER2 Status Na, Hee Young; Choe, Ji-Young; Shin, Seon Ah; Choung, Ho-kyung; Oh, Sohee; Chung, Jin-haeng; Park, Mira; Kim, Ji Eun American Journal of Surgical Pathology, Vol.40 No.12, pp.1622-1630	DOI
2017-01	Quantitative proteomic analysis of HER2 expression in the selection of gastric cancer patients for trastuzumab treatment An, Eunkyung; Ock, Chan Young; Kim, Tae You; Lee, Kyung Hun; Han, Se Won; Im, Seock Ah; Kim, Tae Yong; Liao, Wei Li; Cecchi, Fabiola; Blackler, Adele; Thyparambil, Sheeno; Kim, W. H.; Burrows, Jon; Hembrough, Todd; Catenacci, Daniel V.T.; Oh, Do Youn; Bang, Yung–Jue Annals of Oncology, Vol.28 No.1, pp.110-115	DOI
2017-04	First-in-human phase 1 study of margetuximab (MGAH22), an Fc-modified chimeric monoclonal antibody, in patients with HER2-positive advanced solid tumors Bang, Y. J.; Giaccone, G.; Im, S. A.; Oh, D. Y.; Bauer, T. M.; Nordstrom, J. L.; Li, H.; Chichili, G. R.; Moore, P. A.; Hong, S.; Stewart, S. J.; Baughman, J. E.; Lechleider, R. J.; Burris, H. A. Annals of Oncology, Vol.28 No.4, pp.855-861	DOI
2017-06	Resistance Mechanism against Trastuzumab in HER2-Positive Cancer Cells and Its Negation by Src Inhibition Jin, Mei Hua; Nam, Ah-Rong; Park, Ji Eun; Bang, Ju-Hee; Bang, Yung-Jue; Oh, Do-Youn Molecular Cancer Therapeutics, Vol.16 No.6, pp.1145-1154	DOI

1 2